LV10921B - Novel pharmaceutical formulations - Google Patents

Novel pharmaceutical formulations Download PDF

Info

Publication number
LV10921B
LV10921B LVP-93-1024A LV931024A LV10921B LV 10921 B LV10921 B LV 10921B LV 931024 A LV931024 A LV 931024A LV 10921 B LV10921 B LV 10921B
Authority
LV
Latvia
Prior art keywords
chloro
hydroxyethyl
methylthiazole
treatment
pharmaceutically acceptable
Prior art date
Application number
LVP-93-1024A
Other languages
English (en)
Latvian (lv)
Other versions
LV10921A (lv
Inventor
Bernard Robin Boar
Alan John Cross
Alfred Richard Green
Curt-Eric Hagberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of LV10921A publication Critical patent/LV10921A/xx
Publication of LV10921B publication Critical patent/LV10921B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-93-1024A 1990-08-15 1993-08-10 Novel pharmaceutical formulations LV10921B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole

Publications (2)

Publication Number Publication Date
LV10921A LV10921A (lv) 1995-12-20
LV10921B true LV10921B (en) 1996-08-20

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1024A LV10921B (en) 1990-08-15 1993-08-10 Novel pharmaceutical formulations

Country Status (26)

Country Link
US (1) US5385921A (es)
EP (1) EP0619734B1 (es)
JP (1) JP3094077B2 (es)
AT (1) ATE164066T1 (es)
AU (1) AU657490B2 (es)
BG (1) BG97446A (es)
CA (1) CA2088775A1 (es)
CZ (1) CZ279586B6 (es)
DE (1) DE69129126T2 (es)
DK (1) DK0619734T3 (es)
ES (1) ES2114891T3 (es)
FI (1) FI930608A (es)
HU (1) HUT65821A (es)
IE (1) IE912818A1 (es)
IL (1) IL99169A (es)
IS (1) IS3743A7 (es)
LT (1) LT3978B (es)
LV (1) LV10921B (es)
NO (1) NO303447B1 (es)
NZ (1) NZ239329A (es)
PT (1) PT98688B (es)
RO (1) RO112994B1 (es)
RU (1) RU2093155C1 (es)
SE (1) SE9002659D0 (es)
SK (1) SK8793A3 (es)
WO (1) WO1992003134A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
BG97446A (en) 1994-03-24
IS3743A7 (is) 1992-02-16
NZ239329A (en) 1994-11-25
CZ279586B6 (cs) 1995-05-17
EP0619734B1 (en) 1998-03-18
LTIP1714A (en) 1995-09-25
IL99169A0 (en) 1992-07-15
IL99169A (en) 1995-10-31
HU9300388D0 (en) 1993-04-28
LV10921A (lv) 1995-12-20
HUT65821A (en) 1994-07-28
SK8793A3 (en) 1993-07-07
PT98688A (pt) 1992-07-31
CZ16693A3 (en) 1994-02-16
SE9002659D0 (sv) 1990-08-15
LT3978B (en) 1996-06-25
RU2093155C1 (ru) 1997-10-20
NO930452L (no) 1993-02-09
JP3094077B2 (ja) 2000-10-03
FI930608A0 (fi) 1993-02-11
AU657490B2 (en) 1995-03-16
NO930452D0 (no) 1993-02-09
DE69129126D1 (de) 1998-04-23
AU8409291A (en) 1992-03-17
DK0619734T3 (da) 1998-10-05
NO303447B1 (no) 1998-07-13
WO1992003134A1 (en) 1992-03-05
DE69129126T2 (de) 1998-07-23
CA2088775A1 (en) 1992-02-16
EP0619734A1 (en) 1994-10-19
FI930608A (fi) 1993-02-11
ES2114891T3 (es) 1998-06-16
JPH06500097A (ja) 1994-01-06
PT98688B (pt) 1999-01-29
ATE164066T1 (de) 1998-04-15
IE912818A1 (en) 1992-02-26
RO112994B1 (ro) 1998-03-30
US5385921A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
US7074826B2 (en) R-NSAID esters and their use
JP2009102334A (ja) 神経変性疾患治療剤
CN107163012B (zh) 一类3-烃基-5,6-二氧取代苯酞化合物及其制备方法和用途
US8119839B2 (en) Carboxylic acid and antidepressant composition containing the same as active ingredient
WO2001021206A1 (fr) MOYENS DE PREVENTION OU REMEDES CONTRE LA MYOCARDITE, LA CARDIOMYOPATHIE DILATEE ET L'INSUFFISANCE CARDIAQUE CONTENANT DES INHIBITEURS NF-λB EN TANT QU'INGREDIENT ACTIF
US20140194458A1 (en) Derivate, preparation method and use of 10-methoxycamptothecine
US5385921A (en) Pharmaceutical formulations
JP2006273741A (ja) ＰＰＡＲγリガンド活性を有する組成物
US9802962B2 (en) Tricyclic pyrone compounds reduce amyloid beta aggregates
WO2017100703A1 (en) Ems analogues of lyn/src-tyrosine kinase inhibitors
NO330528B1 (no) Nye salter av benzazepinforbindelser, fremgangsmater for fremstilling derav, og anvendelse av slike i farmasoytiske sammensetninger
JPH10237093A (ja) マツホド抽出成分を含む抗炎症剤
JPH08231396A (ja) 抗ヘリコバクター・ピロリ薬
CN107868032B (zh) 一种取代的苯基丙酸化合物对映异构体及其制备方法、组合物和应用
TW200302091A (en) Methods of treating sepsis
JPH0867627A (ja) 肝疾患治療用組成物
US20210052537A1 (en) Colitis ameliorating agent
CN111514141A (zh) 化合物在制备治疗肝纤维药物中的用途
KR20100050305A (ko) 해면동물 포바스 구쿨렌시스로부터 추출된 신규화합물인 구쿨레닌 ａ와 ｂ, 이의 분리방법 및 이를 이용한 항암제
JPH04295479A (ja) 抗炎症剤
JPH0413676A (ja) 腫瘍壊死因子遊離抑制剤